

FORMATO EUROPEO
PER IL CURRICULUM
VITAE

INFORMAZIONI PERSONALI



Nome Sara Pusceddu
Indirizzo
Telefono
Fax
E-mail sara.pusceddu@istitutotumori.mi.it

Nazionalità Italiana

Data di nascita 13 novembre 1979

ESPERIENZA LAVORATIVA

- **Date (da – a)** **Aprile 2015 – In corso**
- **Nome e indirizzo del datore di lavoro** Fondazione IRCCS, Istituto Nazionale Tumori.
Via Venezian 1, 20133, Milano.
- **Tipo di azienda o settore** Struttura complessa Oncologia Medica I
- **Tipo di impiego** Dirigente Medico di I livello.
- **Principali mansioni e responsabilità** *Gestione clinica di pazienti affetti da neoplasie solide. Partecipazione e conduzione di protocolli di ricerca.*
Principali aree d'interesse: tumori neuroendocrini, tumori del distretto gastro-enterico, in particolare bilio-pancreatico.

- **Date (da – a)** **Novembre 2008 – Marzo 2015**
- **Nome e indirizzo del datore di lavoro** Fondazione IRCCS, Istituto Nazionale Tumori.
Via Venezian 1, 20133, milano.
- **Tipo di azienda o settore** Struttura complessa Oncologia Medica
- **Tipo di impiego** Contratto collaborazione coordinata continuativa (co.co.co), successivamente contratto di collaborazione coordinata professionale (co.co.pro) in qualità di Oncologo Medico
- **Principali mansioni e responsabilità** *Gestione clinica di pazienti affetti da neoplasie solide. Partecipazione e conduzione di protocolli di ricerca.*
Principali aree d'interesse: tumori neuroendocrini, tumori del distretto gastro-enterico, tumori del distretto genito-urinario, melanomi, tumori del distretto toracico.

- **Date (da – a)** **Giugno 2005 – ottobre 2008**
- **Nome e indirizzo del datore di lavoro** Fondazione IRCCS, Istituto Nazionale Tumori.
Via Venezian 1, 20133, Milano.
- **Tipo di azienda o settore** Struttura complessa Oncologia Medica II

- **Tipo di impiego**
- **Principali mansioni e responsabilità**

Medico Specializzando in Oncologia.

Gestione clinica di pazienti affetti da neoplasie solide. Partecipazione e conduzione di protocolli di ricerca.

Principali aree d'interesse: tumori neuroendocrini, tumori del distretto gastro-enterico, tumori del distretto genito-urinario, melanomi, tumori del distretto toracico.

ISTRUZIONE E FORMAZIONE

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita
- Livello nella classificazione nazionale (se pertinente)

3 novembre 2008

Università degli studi di Milano

Scuola di Specializzazione in Oncologia Medica

Oncologia medica

Diploma di Specialità in Oncologia Medica voto 70/70 e lode

Titolo tesi: Tumori Neuroendocrini a sede primitiva ignota, rarità o neoplasia misconosciuta?

Studio Osservazionale, Retrospectivo, Monoistituzionale.

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione

8 marzo 2005

Ordine dei Medici di Cagliari

- Qualifica conseguita

Abilitazione all'esercizio della professione medica ed iscrizione all'Albo dei Medici Chirurghi della Provincia di Cagliari al numero 8506

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione

1998-2004

Università degli Studi di Cagliari

Facoltà di Medicina e Chirurgia

- Qualifica conseguita
- Principali materie / abilità professionali oggetto dello studio

22 luglio 2004 Laurea in Medicina e Chirurgia

110/110 e Lode, Abbraccio accademico, Medaglia agli studi

TitoloTesi: Neoplasie a cellule germinali del testicolo: nostra esperienza

CAPACITÀ E COMPETENZE PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

PRIMA LINGUA

Italiano

ALTRE LINGUE

- Capacità di lettura
- Capacità di scrittura
 - Capacità di espressione orale

Inglese

buona

buona

buona

ALTRE LINGUE

- Capacità di lettura

Francese

buona

- *Capacità di scrittura* buona
- *Capacità di espressione orale* buona

CAPACITÀ E COMPETENZE TECNICHE Buona capacità utilizzo PC (Word, Power point, Excel, Outlook, Internet)
Con computer, attrezzature specifiche, macchinari, ecc.

CAPACITÀ E COMPETENZE ARTISTICHE Discreta abilità a suonare il pianoforte.
Musica, scrittura, disegno ecc.

PATENTE O PATENTI Patente di guida categoria B

RICONOSCIMENTI:

Agosto 2001: Repubblica di Malta: borsa di studio del governo maltese per studenti Italiani meritevoli, indirizzata allo studio della lingua inglese.

Giugno 2003: AMMI (Associazione Mogli medici italiani): assegno di studio per miglior curriculum studio rum

Marzo 2012: Vincitrice del Flims Clinical Research Workshop 2012 per il progetto: A single arm phase II, single center, clinical trial of AMG386 in combination with Sunitinib in pretreated patients with pancreatic well differentiated neuroendocrine tumor (pWDNET).

ALTRE CAPACITÀ E COMPETENZE **ATTIVITA'DI RICERCA**
Competenze non precedentemente indicate.

RESPONSABILITÀ DI STUDI FINANZIATI DOPO APPLICATION GRANT

- 2016: research grant (Ipsen S.p.A.). Principal Investigator of the trial "Safety of Lanreotide 120 mg ATG in combination with Metformin in patients with progressive advanced well-differentiated gastrointestinal (GI) or lung carcinoids. The pilot, one-arm, open-label, prospective study: the MetNET-2 trial. Prot. INT 180/15.
Funded budget for the study: 202.000 euro
- 2017: research grant (PFIZER S.p.A) Principal Investigator of the project "immunohistochemical analysis of pRB, CICLINA D1, CDK4 in small intestinal and bronco pulmonary neuroendocrine tumours". PI: Dr. Sara Pusceddu. Prot. 165/17
Funded budget for the analysis: 6.000 euro
- 2019: research grant (Ipsen S.p.A.). principal Investigator of the trial "A phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumour (NET): The LOLA trial" Prot. INT 240/19.
Funded budget for the analysis: 459.426 euro

RESPONSABILITÀ (PRINCIPAL INVESTIGATOR) OR SUB-INVESTIGATOR DI STUDI CLINICI PROSPETTICI O RETROSPETTIVI A CARATTERE CLINICO-TRASLAZIONALE

Anno	Titolo del Progetto	PI dello studio	N INT	Ruolo nello Studio	
Feb 2008	Efficacy and Safety of RAD001 (Everolimus) in Patients Affected by Biliary Tract Cancer Progressing after Prior Chemotherapy: a Phase II I.T.M.O. Study.	Emilio Bajetta, MD Fondazione IRCCS Istituto Tumori Milano	02/08	Sara Pusceddu, MD Co-investigator	No-Profit
Feb 2008	Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: a phase II trial. ITMO group study	Emilio Bajetta, MD Fondazione IRCCS Istituto Tumori Milano	02/08	Sara Pusceddu, MD Co-investigator	No-Profit
April 2011	Compassionate use of RAD001 (Everolimus) in neuroendocrine tumours	Buzzoni Roberto, MD Fondazione IRCCS Istituto Tumori Milano	C-RAD001	Sara Pusceddu, MD Co-investigator	Profit
Jun 2012	A multicenter, two stage, phase II study, evaluating the efficacy of oral BEZ235 plus best supportive care (BSC) versus placebo plus BSC in the treatment of patients with advanced pancreatic neuroendocrine tumors (pNET) after failure of mTOR inhibitor therapy	Buzzoni Roberto, MD Fondazione IRCCS Istituto Tumori Milano	06/12	Sara Pusceddu, MD Co-investigator	Profit
July 2012	Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors (RADIANT- III)	Buzzoni Roberto, MD Fondazione IRCCS Istituto Tumori Milano	22/12	Sara Pusceddu, MD Co-investigator	Profit
Febr 2012	Activity and safety of Sunitinib in advanced Pheocromocitoma/paraganglioma. A Phase II study (SUTNET Trial)	Buzzoni Roberto, MD Fondazione IRCCR Istituto Tumori Milano	42/11	Sara Pusceddu, MD Co-investigator	No-Profit
May 2013	Multicentric, open-label, rollover, follow up study of RADIANT-III	Buzzoni Roberto, MD Fondazione IRCCS Istituto Tumori Milano	46/13	Sara Pusceddu, MD Co-investigator	Profit
Oct 2013	A multicentre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumours NETTER-1 Trial	Ettore Seregni, MD Fondazione IRCCS Istituto Tumori Milano	79/13	Sara Pusceddu, MD Co-investigator	Profit
Jul 2014	A monocentric, phase II study, evaluating the activity and safety of Everolimus plus Octreotide LAR and Metformin in advanced well differentiated pancreatic neuroendocrine tumours. A Phase II study (Met-NET-1 Trial)	Filippo de Braud, MD Fondazione IRCCS Istituto Tumori Milano	45/14	Sara Pusceddu, MD Co-investigator	No-Profit
Apr 2015	Follow up to the AVANT Study up to 8 and 10 Years (Median Follow up) in Patients With Colon Carcinoma	Buzzoni Roberto, MD Fondazione IRCCS Istituto Tumori Milano	26/15	Sara Pusceddu, MD Co-investigator	Profit
Jan 2015	A Phase II, open-label, multicenter trial to investigate the clinical activity and safety of MSB0010718C (AVELUMAB) in	Buzzoni Roberto, MD Fondazione IRCCR Istituto Tumori Milano	151/14	Sara Pusceddu, MD Co-investigator	Profit

	subjects with Merkel cell carcinoma				
Jun 2015	A multicentric, observational study, evaluating the impact of Metformin in advanced pancreatic neuroendocrine tumours treated with Everolimus +/- somatostatin analogues. The (Pancreatic Retrospective Italian Metformin) PRIME-NET study)	Filippo de Braud, MD Fondazione IRCCS Istituto Tumori Milano	85/15	Sara Pusceddu, MD Co-investigator	No-Profit
Jan 2016	Efficacy and safety of lanreotide autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide autogel® 120 mg administered every 28 days	Buzzoni Roberto, MD Fondazione IRCCS Istituto Tumori Milano	141/15	Sara Pusceddu, MD Co-investigator	Profit
Apr 2016	Safety of Lanreotide 120 mg ATG in combination with Metformin in patients with progressive advanced Well-differentiated gastro-intestinal (GI) or lung carcinoids. A pilot, one-arm, open-label, prospective study: the MetNET-2 trial	Pusceddu Sara, MD Fondazione IRCCS Istituto Tumori Milano	180/15	Sara Pusceddu Principal Investigator	No-Profit
Mar 2017	An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic non-functional neuroendocrine tumors of pancreatic gastrointestinal (GI), or thoracic origin who have progressed on prior treatment	Pusceddu Sara, MD Fondazione IRCCS Istituto Tumori Milano	07/17	Sara Pusceddu Principal Investigator	No-Profit
Apr 2017	A multicenter, randomized, phase II, evaluating the activity and safety of FOLFIRI versus CAPTEM in the treatment of patients with advanced poorly differentiated neuroendocrine tumors (NEC G3) after failure of first line chemotherapy cisplatinun based. The SENECA study	Pusceddu Sara, MD Fondazione IRCCS Istituto Tumori Milano	IRST10 0.22	Sara Pusceddu Principal Investigator	No-Profit
March 2017	Immunohistochemical analysis of pRB, CICLINA D1, CDK4 in small intestinal and bronco pulmonary neuroendocrine tumours.	Pusceddu Sara, MD Fondazione IRCCS Istituto Tumori Milano	INT 165/17	Sara Pusceddu Principal Investigator	No-Profit
March 2017	CPDR001E2201 An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced well-differentiated, non-functional GEP, or thoracic origin or poorly-differentiated GEP-NEC, that have progressed on prior treatment.	Pusceddu Sara, MD Fondazione IRCCS Istituto Tumori Milano	INT 07/17	Sara Pusceddu Principal Investigator	Profit

May 2018	PRRT Studio multicentrico osservazionale: impatto clinico dell'impiego degli Analoghi della Somatostatina (SSA) in combinazione a Peptide Receptor Radionuclide Therapy (PRRT) vs PRRT esclusiva, nei tumori neuroendocrini ben differenziati, avanzati	Pusceddu Sara, MD Fondazione IRCCS Istituto Tumori Milano	INT 31/18	Sara Pusceddu Principal Investigator	No-Profit
May 2019	POD1UM-201 A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma	Filippo de Braud, MD Fondazione IRCCS Istituto Tumori Milano	INT 01/19	Sara Pusceddu, MD Co-investigator	Profit
Sept 2020	NETTER-2 multicente, randomized, open-label, phase III study in patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP-NETs..	Ettore Seregni, MD Fondazione IRCCS Istituto Tumori Milano	INT 243/19	Sara Pusceddu, MD Co-investigator	Profit
Jun 2020	Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in GEP and thoracic NET: The LOLA trial	Pusceddu Sara, MD Fondazione IRCCS Istituto Tumori Milano	INT 240/19	Sara Pusceddu Principal Investigator	No-Profit
Jul 2020	INTENSIVE prospective TRIAL InterNaTional rEgistry oN Sars-cov-2 positive nEuroendocrine neoplasm patients	Filippo de Braud, MD Fondazione IRCCS Istituto Tumori Milano	INT 299/20	Sara Pusceddu Principal Investigator	No-Profit
Sept 2021	Phase III study to evaluate efficacy and safety of PRRT with ¹⁷⁷ Lu-Edotreotide compared to Everolimus in pts with inoperable, progressive, SSTR+, GEP NETs COMPITE Trial	Marco Maccauro, MD Fondazione IRCCS Istituto Tumori Milano		Sara Pusceddu Sub-Investigator	Profit
May 2022	ITANET-Registry: raccolta multicentrica dei casi di Tumore Neuroendocrino Gastro-Entero-Pancreatico	Filippo de Braud, MD Fondazione IRCCS Istituto Tumori Milano		Sara Pusceddu Sub-Investigator	No-Profit
Nov 2022	Window-of-opportunity study of chemo-immunotherapy in patients with resectable Merkel Cell Carcinoma prior to surgery: the MERCURY trial	Morano Federica, MD Fondazione IRCCS Istituto Tumori Milano		Sara Pusceddu Sub-Investigator	No-Profit Grant
FEB 2023	Fattori predittivi risposta PRRT	Pusceddu Sara, MD Fondazione IRCCS Istituto Tumori Milano	INT 30/20	Sara Pusceddu Principal Investigator	No-Profit
Feb 2024	Studio italiano multicentrico di fase II con Temozolomide metronomica in pazienti "fragili" con neoplasia neuroendocrina avanzata (NENs): MeTe study	Pusceddu Sara, MD Fondazione IRCCS Istituto Tumori Milano	INT 61/23	Sara Pusceddu Principal Investigator	No-Profit
MAY 2024	Agnostic therapy in a phase II, multicenter, single-arm study in first-line treatment of durvalumab (medi 4736) in association with carboplatin or cisplatin and etoposide in patients affected by extensive stage - extrapulmonary small cell carcinoma (epsc) –	Pusceddu Sara, MD Fondazione IRCCS Istituto Tumori Milano		Sara Pusceddu Principal Investigator	No-Profit

	durvascc trial"				
AUG 2024	Phase II, open label, single arm study of P embrolizum A b combi N e D with cisplatin or carb O platin and etoposide in treatment naïve advanced me R kel cell c A rcinoma (MCC) (PANDORA Trial).	Pusceddu Sara, MD Fondazione IRCCS Istituto Tumori Milano		Sara Pusceddu Principal Investigator	No-Profit

CAPACITA' DI ORGANIZZAZIONE E PARTECIPAZIONE A GRUPPI DI RICERCA/COMITATI SCIENTIFICI/ GRUPPI DI LAVORO

ANNO	Gruppo ricerca/ comitati scientifici/ gruppi di lavoro
2008-2010	Coordinamento della redazione degli "Algoritmi terapeutici della struttura complessa OM2 della Fondazione IRCCS Istituto Nazionale tumori Milano "
2009	Membro gruppo di lavoro per la stesura delle basi scientifiche per la definizione di linee guida in ambito clinico per i Tumori Neuroendocrini del tratto Gastro-Entero-Pancreatico (GEP). Alleanza contro il cancro febbraio 2009.
Dal Dicembre 2010 – in corso	Riconoscimento ufficiale dalla Direzione scientifica della Fondazione IRCCS Istituto Tumori di Milano quale Expert in Medical Oncology Tumor-board GEP-NET on ENETS Center of Excellence Fondazione IRCCS Istituto Tumori Milano
2011-2012	Membro gruppo di lavoro Stesura linee guida ROL (rete oncologica Lombarda) relative al trattamento dei tumori neuroendocrini.
2013-2014	Gruppo di lavoro per la stesura dell'ESMO CD-ROM Neuroendocrine tumours Spotlights
2013- in corso	Membro gruppo di lavoro Stesura linee guida Nazionali ITANET-AIOM relative al trattamento dei tumori neuroendocrini.
2015-2018	Membro comitato promotore "web site" della Società Italiana per i Tumori Neuroendocrini (ITANET)
2016-2019	Gruppo di lavoro per la stesura dell' ESMO book "Neoplasm for the lung. Guidelines for Clinicians - chapter lung neuroendocrine tumours-"
Dal 2018 – in corso	Membro del Consiglio direttivo della Società Italiana per i Tumori Neuroendocrini (ITANET) e coordinatore della Task force progetti e studi clinici della Società scientifica

NUMEROSE PARTECIPAZIONI IN QUALITA' DI RELATORE/COMITATO SCIENTIFICO DI INTERESSE NAZIONALE ED INTERNAZIONALE TRA LE QUALI:

- 2016 ESMO Annual Meeting: Oral presentation: "Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues".
- 2021 ENETS Annual Meeting: invited presentation: "Treatment outcome in NEN patients with Diabetes. Basic Conditions and Impact of Therapy".

- 2022 ENETS Annual Meeting: Oral presentation: Safety of Lanreotide Autogel 120 mg plus Metformin in patients with advanced, well-differentiated gastro-intestinal or lung neuroendocrine tumors. A pilot, open-label, prospective study: the MetNET-2 trial (NCT02823691)

PUBBLICAZIONI (esclusi abstract):

1. **Sara Pusceddu**, Sara Pani, Giuseppe Procopio. **Ketoconazolo in associazione ad idrocortisone in paziente con carcinoma prostatico in fase avanzata**. Casi Clinici in Oncologia. Numero 18, settembre 2006.
2. Bajetta E, Celio L, Ferrario E, Di Bartolomeo M, Denaro A, Dotti K, Mancin M, Bajetta R, Colombo A. and **Pusceddu S. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer**. Ann Oncol. 2007 Nov;18(11):1810-6. Epub 2007 Sep 6.
3. Procopio G, Verzoni E, Gevorgyan A, Mancin M, **Pusceddu S**, Catena L, Platania M, Guadalupi V, Martinetti A, Bajetta E. **Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma**. Oncology. 2007;73(3-4):204-9.
4. **Pusceddu S**, Bajetta E, Buzzoni R, Carcangiu ML, Platania M, Del Vecchio M, Ditto A. **Primary uterine cervix melanoma resembling malignant peripheral nerve sheath tumor: a case report**. Int J Gynecol Pathol. 2008 Oct;27(4):596-600.
5. **Sara Pusceddu**, Monika Ducceschi, Roberto Buzzoni. **Melanoma maligno della cervice uterina con presentazione morfologica ed immunofenotipica di tumore maligno della guaina mielinica dei nervi periferici**. Casi Clinici in Oncologia. Numero 27, dicembre 2008
6. Emilio Bajetta, Giuseppe Procopio, **Sara Pusceddu**, Filippo Pietrantonio, Massimo Milione, Marco Maccauro, Elena Verzoni, Valentina Guadalupi, Marco Platania. **From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours**. Oncology Review (2009) 3:79-87
7. Emilio Bajetta, Giuseppe Procopio, Andrea Colombo, Valentina Guadalupi, Elena Verzoni, Filippo Pietrantonio, **Sara Pusceddu**, Mariangela Manzoni, Arpine Gevorgyan and Roberto Buzzoni. **Sorafenib in Hepatocellular Carcinoma**. Clinical Medicine: Therapeutics 2009;1:277-287.
8. Bajetta E, Catena L, Ducceschi M, **Pusceddu S**, Milione M, Maccauro M, Bajetta R, Procopio G, Buzzoni R, Formisano B, Di Guardo L, Platania M. **Pitfalls in the diagnosis of neuroendocrine tumors: atypical clinical and radiological findings as cause of medical mistakes**. Tumori. 2009 Jul-Aug;95(4):501-7.
9. Emilio Bajetta, **Sara Pusceddu**, Valentina Guadalupi, Monika Ducceschi, Luigi Celio. **Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron**. Cancer Manag Res. 2009 Aug 10;1:89-97
10. Co-autore della **Raccolta casi clinici premio Lanreotide nei tumori neuroendocrini**. Autori: Emilio Bajetta, **Sara Pusceddu**, Ettore Bichisao. Supplemento della rivista casi clinici in oncologia 12/2009.
11. Valentina Guadalupi, **Sara Pusceddu**, Giuseppe Procopio. **Carcinoma neuroendocrino ben differenziato dell'ileo con metastasi epatiche: remissione completa di malattia dopo trattamento multimodale**. Suppl. rivista casi clinici in oncologia 12/2009 "Premio Ipsen Lanreotide".
12. **Algoritmi terapeutici della struttura complessa OM2** della Fondazione IRCCS Istituto Nazionale tumori Milano edizione **2009 Sara Pusceddu**: curatore del testo e co-autore del capitolo: Carcinoma della mammella terapia della fase avanzata I e II.
13. **Algoritmi terapeutici della struttura complessa OM2** della Fondazione IRCCS Istituto Nazionale tumori Milano edizione **2010. Sara Pusceddu**: curatore del testo e co-autore dei capitoli relativi al carcinoma del pancreas, carcinoma della colecisti e delle vie biliari intra ed

extra epatiche, carcinoma della mammella terapia della fase avanzata I e II, carcinoma neuroendocrini GEP, polmonari, carcinoma midollare della tiroide, feocromocitoma, paraganglioma.

14. **Pusceddu S**, Catena L, Valente M, Buzzoni R, Formisano B, Del Vecchio M, Ducceschi M, Tavecchio L, Frabbri A, Bajetta E. **Long-term follow up of patients affected by pulmonary carcinoid at the Istituto Nazionale Tumori of Milan a retrospective analysis.** J Thorac Dis. 2010 Mar;2(1):16-20
15. Valente M, Catena L, Milione M, **Pusceddu S**, Formisano B, Bajetta E. **Common diagnostic challenges in the histopathologic diagnosis of neuroendocrine lung tumors: a case report.** Case Rep Oncol. 2010 Jul 2;3(2):202-207
16. **La famiglia dei carcinoidi capitolo la terapia medica.** Autori :Buzzoni Roberto, Monika Ducceschi, **Sara Pusceddu**. Compendio per i medici di famiglia in occasione dell'evento formativo ECM n 843-1001790. Milano 30/01/2010.
17. **A clinical Approach to carcinoid tumors. Update in clinical Endocrinology, Sara Pusceddu.** 10th AME (Italian Association of Clinical Endocrinologists) Italian meeting, 5th Joint Meeting with AACE (American Association of Clinical Endocrinologists), Naples 5-7, 2010. Handout.
18. Monika Ducceschi, **Sara Pusceddu**, Marco Platania. **False positives and false negatives in neuroendocrine tumors diagnosis: clinical reports.** Tumori, 96: 827-832, 2010.
19. Marco Platania, Francesco Agustoni, Barbara Formisano, Milena Vitali, Monika Ducceschi, Filippo Pietrantonio, Nicoletta Zilembo, Francesco Gelsomino, **Sara Pusceddu** and Roberto Buzzoni. **Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer** Target Oncol. 2011 Sep;6(3):181-6.
20. **Sara Pusceddu**, Massimo Milione, and Giuseppe Procopio. **Compassionate Use of Everolimus in a Patient With a Neuroendocrine Tumor: A Case Report and Discussion of the Literature.** Oncol Res. 2011;19(8-9):403-6.
21. **Sara Pusceddu.** **Approccio terapeutico al paziente affetto da carcinoma neuroendocrino del pancreas avanzato: attività antiproliferativa degli analoghi della somatostatina** Handout. Update in clinical Endocrinology, 11th AME (Italian Association of Clinical Endocrinologists) Italian meeting, Udine 14-16 ottobre, 2011.
22. Catena L, Bichisao E, Milione M, Valente M, Platania M, **Pusceddu S**, Ducceschi M, Zilembo N, Formisano B, Bajetta E. **Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?** Tumori. 2011 Sep-Oct;97(5):564-7. doi: 10.1700/989.10712.
23. **Pusceddu S**, Bajetta E, Carcangiu ML, Formisano B, Ducceschi M, Buzzoni R. **A literature overview of primary cervical malignant melanoma: An exceedingly rare cancer.** Crit Rev Oncol Hematol.(2011) Crit Rev Oncol Hematol. 2012 Feb;81(2):185-95.
24. M. Milione , **S. Pusceddu**, P. Gasparini, F. Melotti, P. Maisonneuve, V. Mazzaferro, FG. de Braud and G.Pelosi **Succinate Dehydrogenase B Subunit Immunohistochemical Expression Predicts Aggressiveness in Well Differentiated Neuroendocrine Tumors of the Ileum.** Cancers 2012, 4(3), 808-820; doi:10.3390/cancers4030808
25. Procopio G, Pusceddu S, Buzzoni R. **Sunitinib and everolimus in pancreatic neuroendocrine tumors.**Tumori. 2012 May-Jun;98(3):394. doi: 10.1700/1125.12411.
26. **Pusceddu S**, Buzzoni R, De Braud F. **Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm?**. Ann Oncol. 2013 Mar 13.
27. Buzzoni R, **Pusceddu S**, Damato A, Meroni M, Cumali A, Milione M, Mazzaferro V, De Braud F, Spreafico C, Maccauro M, Zaffaroni N, Castellani M.R. **Malignant pheochromocytoma and paragangliona: future considerations for therapy.** QJNucl Med Imaging 2013, 57:1-2.

28. Damato A, **Pusceddu S**, Milione M, Mazzaferro V, Magli M, Seregini E, De Braud F and Buzzoni R. **Well-Differentiated Neuroendocrine Tumor of Tailgut Cyst. A Rare Entity with Controversial Medical Opportunities.** Tumori. 2013 Jul-Aug;99(4):148e-51e.
29. Procopio G, Verzoni E, Testa I, Garanzini E, Montone R, **Pusceddu S**, Biondani P, Grassi P. Future Directions in Metastatic Castration Resistant Prostate Cancer (mCRPC): **Clinical Rationale and Use of New-Generation Hormonal Therapies.** Journal of Cancer Therapy 2013 ID: 8901592.
30. Co-autore del Manuale intitolato: **L'ottimizzazione del percorso diagnostico Terapeutico del paziente NET: l'esperienza dell'Istituto Nazionale dei Tumori.** Autori: Filippo De Braud, **Sara Pusceddu**, Buzzoni Roberto, Massimo Milione.
31. Co-autore del Capitolo intitolato: **Le neoplasie neuroendocrine**, Nuova edizione del Volume MEDICINA ONCOLOGICA 2013. Autori: Filippo De Braud, **Sara Pusceddu**, Buzzoni Roberto.
32. Co-autore del Manuale intitolato: **Raccomandazioni sulla gestione dei NETs** Autori: Emilio Bajetta, Adelmo Antonucci, Salvatore Artale, Alfredo Berruti, Roberto Buzzoni, Carlo Carnaghi, Laura Catena, Fernando Cirillo, Nicola Fazio, Marco Manzoni, Massimo Milione, **Sara Pusceddu**. Aggiornamenti in Onc Synergie in medicina N. 1 - Ottobre 2013 - Anno XVI.
33. Co-Autore degli **Spotlights 2013 neuroendocrine tumours ESMO 2013.** Autori Filippo De Braud, **Sara Pusceddu**. ESMO Congress, Amsterdam 2013
34. Co-autore del capitolo **Neuroendocrine tumors of lung origin.** Autori: Marina Garassino, **Sara Pusceddu**, Andrea Billè. Essentials for Clinicians ESMO 2014.
35. **Pusceddu S**, Vitali M, Haspinger E, Tavecchio L, Giovannetti R, Bille A, Concas L, Garassino M, Milione M, de Braud F, Buzzoni R. **Update on Therapeutic Strategy in Lung Carcinoids** *Journal of Cancer Therapy*, 2013, 4, 1466-1471.
36. Bajetta E, Catena L, Biondani P, **Pusceddu S**, Valente M, Bianco N, Novelli E. **Activity of a Three-drug Combination Including Cisplatin (CLOVER Regimen) for Poorly Differentiated Neuroendocrine Carcinoma.** Anticancer Res. 2014 Oct;34(10):5657-60.
37. Verzoni E, **Pusceddu S**, Buzzoni R, Garanzini E, Damato A, Biondani P, Testa I, Grassi P, Bajetta E, DeBraud F, Procopio G. **Safety profile and treatment response of everolimus in different solid tumors: an observational study.** Future Oncol. 2014;10(9):1611-7. doi: 10.2217/fon.14.31.
38. Platania M, Valeri B, Marchianò A, Calareso G, Agustoni F, Haspinger E, **Pusceddu S**, Garassino MC, Gelsomino F, de Braud F. **Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer.** Int J Colorectal Dis. 2014 Aug 21.
39. Buzzoni R, **Pusceddu S**, Bajetta E, De Braud F, Platania M, Iannacone C, Cantore M, Mambrini A, Bertolini A, Alabiso O, Ciarlo A, Turco C, Mazzaferro V. **Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study.** Ann Oncol. 2014 Aug;25(8):1597-603. doi: 10.1093/annonc/mdu175. Epub 2014 May 14.
40. Bajetta E, Catena L, Fazio N, **Pusceddu S**, Biondani P, Blanco G, Ricci S, Aieta M, Pucci F, Valente M, Bianco N, Mauri CM, Spada F. **Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.** Cancer. 2014 Aug 15;120(16):2457-63.
41. **Pusceddu S**, Tessari A, Testa I, Procopio G. **Everolimus in advanced solid tumors: when to start, early or late?** Tumori. 2014 Jan-Feb;100(1):e2-3.
42. **Pusceddu S**, de Braud F, Concas L, Bregant C, Leuzzi L, Formisano B, Buzzoni R. **Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II**

study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors. Tumori. 2014 Nov-Dec;100(6)

43. **Pusceddu S**, Indini, Procopio G. **Everolimus treatment in advanced solid tumors: a personal view.** Future Sci OA. 2015 Nov 1;1(3):FSO3.
44. **Pusceddu S**, De Braud F, Festinese F, Bregant C, Lorenzoni A, Maccauro M, Milione M, Concas L, Formisano B, Leuzzi L, Mazzaferro V, Buzzoni R. **Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.** Future Oncol. 2015;11(13):1947-59.
45. Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, Nobili E, Pastorelli D, Cascinu S, Merlano M, Chiara S, Antonuzzo L, Funaioli C, Spada F, **Pusceddu S**, Fontana A, Ambrosio MR, Cassano A, Campana D, Cartenì G, Appetecchia M, Berruti A, Colao A, Falconi M, Delle Fave G. **Real-world study of everolimus in advanced progressive neuroendocrine tumors.** Oncologist. 2015 May;20(5):570.
46. Vernieri C, Femia D, **Pusceddu S**, Capella C, Rosai J, Calareso G, Concas L, Prinzi N, Lo Russo G, de Braud F, Buzzoni R. **Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up.** Case Rep Oncol. 2016 Aug 17;9(2):432-439.
47. Lo Russo G, **Pusceddu S**, Prinzi N, Imbimbo M, Proto C, Signorelli D, Vitali M, Ganzinelli M, Maccauro M, Buzzoni R, Seregini E, de Braud F, Garassino MC. **Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.** Tumour Biol. 2016 Oct;37(10):12991-13003. Epub 2016 Jul 27.
48. **Pusceddu S**, Femia D, Lo Russo G, Ortolani S, Milione M, Maccauro M, Vernieri C, Prinzi N, Concas L, Leuzzi L, De Braud F, Buzzoni R. **Update on medical treatment of small intestinal neuroendocrine tumors.** Expert Rev Anticancer Ther. 2016 Sep;16(9):969-76.
49. **Pusceddu S**, De Braud F, Lo Russo G, Concas L, Femia D, Vernieri C, Indini A, Formisano B, Buzzoni R. **How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies.** Oncotarget. 2016 Jul 12;7(28):44841-44847. doi: 10.18632/oncotarget.8601.
50. Lo Russo G, **Pusceddu S**, Proto C, Macerelli M, Signorelli D, Vitali M, Ganzinelli M, Gallucci R, Zilembo N, Platania M, Buzzoni R, de Braud F, Garassino MC. **Treatment of lung large cell neuroendocrine carcinoma.** Tumour Biol. 2016 Jun;37(6):7047-57. doi: 10.1007/s13277-016-5003-4. Epub 2016 Mar 4.
51. **Pusceddu S**, Lo Russo G, Macerelli M, Proto C, Vitali M, Signorelli D, Ganzinelli M, Scanagatta P, Duranti L, Trama A, Buzzoni R, Pelosi G, Pastorino U, de Braud F, Garassino MC. **Diagnosis and management of typical and atypical lung carcinoids.** Crit Rev Oncol Hematol. 2016 Apr;100:167-76. doi: 10.1016/j.critrevonc.2016.02.009.
52. **Pusceddu S**, Buzzoni R, Vernieri C, Concas L, Marceglia S, Giacomelli L, Milione M, Leuzzi L, Femia D, Formisano B, Mazzaferro V, de Braud F. **Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.** Future Oncol. 2016 May;12(10):1251-60.
53. **Pusceddu S**, Verzoni E, Prinzi N, Mennitto A, Femia D, Grassi P, Concas L, Vernieri C, Lo Russo G, Procopio G. **Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.** Ther Adv Med Oncol. 2017 Mar;9(3):183-188.
54. Citterio D*, **Pusceddu S* (co-first author)**, Facciorusso A, Coppa J, Milione M, Buzzoni R, Bongini M, deBraud F, Mazzaferro V. **Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver.** Eur J Surg Oncol. 2017 Feb;43(2):380-387.
55. Milione M, Maisonneuve P, Pellegrinelli A, **Pusceddu S**, Centonze G, Dominoni F, Brambilla C, Rubino M, Faggiano A, Buzzoni R, Concas L, Giacomelli L, Coppa J,

- Mazzaferro V, de Braud F. **Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors.** *Endocrine*. 2017 Sep;57(3):512-517.
56. Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L, Pisa E, Barberis M, Vanoli A, Buzzoni R, **Pusceddu S**, Concas L, Sessa F, Solcia E, Capella C, Fazio N, La Rosa S. **The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.** *Neuroendocrinology*. 2017;104(1):85-93.
 57. Bajetta E, Catena L, **Pusceddu S**, Spada F, Iannacone C, Sarno I, Di Menna G, Dottorini L, Marte AM. **Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update.** *Neuroendocrinology*. 2018;106(4):307-311.
 58. **Pusceddu S**, Prinzi N, Lo Russo G, Femia D, Milione M, Perrone F, Tamborini E, Concas L, Pulice I, Vernieri C, Corti F, Buzzoni R, de Braud F. **Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors.** *Future Oncol*. 2017 Aug;13(19):1677-1683.
 59. Berardi R, Torniai M, **Pusceddu S**, Spada F, Ibrahim T, Brizzi MP, Antonuzzo L, Ferolla P, Panzuto F, Silvestris N, Partelli S, Ferretti B, Freddari F, Gucciardino C, Testa E, Concas L, Murgioni S, Bongiovanni A, Zichi C, Riva N, Rinzivillo M, Brunetti O, Giustini L, Di Costanzo F, Delle Fave G, Fazio N, De Braud F, Falconi M, Cascinu S. **Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors.** *Cancer Med*. 2017 Jul;6(7):1493-1499.
 60. **The underestimated role of somatostatin analogs in the NETTER-1 trial. Pusceddu S, Buzzoni R, de Braud F.** *Future Oncol*. 2017 Jun;13(15):1287-1289.
 61. Gallo M, Malandrino P, Fanciulli G, Rota F, Faggiano A, Colao A; NIKE Group (**Pusceddu S**). **Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives.** *J Cancer Res Clin Oncol*. 2017 Jul;143(7):1209-1224.
 62. Femia D, Prinzi N, Anichini A, Mortarini R, Nichetti F, Corti F, Torchio M, Peverelli G, Pagani F, Maurichi A, Mattavelli I, Milione M, Bedini N, Corti A, Di Bartolomeo M, de Braud F, **Pusceddu S.** **Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.** *Target Oncol*. 2018 Oct;13(5):567-582.
 63. Brighi N, La Rosa S, Rossi G, Grillo F, **Pusceddu S**, Rinzivillo M, Spada F, Tafuto S, Massironi S, Faggiano A, Antonuzzo L, Santini D, Sessa F, Maragliano R, Gelsomino F, Albertelli M, Vernieri C, Panzuto F, Fazio N, De Divitiis C, Lamberti G, Colao A, Fave GD, Campana D. **Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study.** *Ann Surg*. 2018 Jul 10.
 64. **Pusceddu S**, Prinzi N, Raimondi A, Corti F, Buzzoni R, Di Bartolomeo M, Seregini E, Maccauro M, Coppa J, Milione M, Mazzaferro V, de Braud F. **Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.** *Tumori*. 2019 Apr;105(2):113-120.
 65. Inno A, Lo Russo G, Salgarello M, Corrao G, Casolino R, Galli G, Modena A, Romano L, **Pusceddu S**, Greco FG, Garassino MC, Gori S. **The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST.** *Tumori*. 2018 Mar-Apr;104(2):88-95.
 66. Nichetti F, Marra A, Corti F, Guidi A, Raimondi A, Prinzi N, de Braud F, **Pusceddu S.** **The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.** *Target Oncol*. 2018 Jun;13(3):333-351.
 67. **Pusceddu S**, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, Ibrahim T, Brizzi MP, Campana D, Faggiano A, Giuffrida D, Rinzivillo M, Cingarlini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi

- C, Davì MV, Cauchi C, Duro M, Ricci S, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, Lo Russo G, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, de Braud F. **Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.** *Gastroenterology*. 2018 Aug;155(2):479-489.e7.
68. **Pusceddu S**, Barretta F, Trama A, Botta L, Milione M, Buzzoni R, De Braud F, Mazzaferro V, Pastorino U, Seregni E, Mariani L, Gatta G, Di Bartolomeo M, Femia D, Prinzi N, Coppa J, Panzuto F, Antonuzzo L, Bajetta E, Brizzi MP, Campana D, Catena L, Comber H, Dwane F, Fazio N, Faggiano A, Giuffrida D, Henau K, Ibrahim T, Marconcini R, Massironi S, Žakelj MP, Spada F, Tafuto S, Van Eycken E, Van der Zwan JM, Žagar T, Giacomelli L, Miceli R; NEPScore Working Group. **A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors.** *Endocr Relat Cancer*. 2018 Jun;25(6):607-618.
 69. Vernieri C, Nichetti F, Raimondi A, **Pusceddu S**, Platania M, Berrino F, de Braud F. **Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives.** *Crit Rev Oncol Hematol*. 2018 Mar;123:57-73.
 70. Rinzivillo M, Fazio N, **Pusceddu S**, Spallanzani A, Ibrahim T, Campana D, Marconcini R, Partelli S, Badalamenti G, Brizzi MP, Catena L, Schinzari G, Carnaghi C, Berardi R, Faggiano A, Antonuzzo L, Spada F, Gritti S, Femia D, Gelsomino F, Bongiovanni A, Ricci S, Brighi N, Falconi M, Delle Fave G, Panzuto F. **Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.** *Pancreatology*. 2018 Mar;18(2):198-203.
 71. Campana D, Walter T, **Pusceddu S**, Gelsomino F, Graillot E, Prinzi N, Spallanzani A, Fiorentino M, Barritault M, Dall'Olio F, Brighi N, Biasco G. **Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.** *Endocrine*. 2018 Jun;60(3):490-498.
 72. Petrelli F, Ghidini A, Torchio M, Prinzi N, Trevisan F, Dallera P, De Stefani A, Russo A, Vitali E, Bruschi L, Costanzo A, Seghezzi S, Ghidini M, Varricchio A, Cabiddu M, Barni S, de Braud F, **Pusceddu S**. **Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis.** *Radiother Oncol*. 2019 May;134:211-219.
 73. **Pusceddu S**, Ghidini M, Torchio M, Corti F, Tomasello G, Niger M, Prinzi N, Nichetti F, Coinu A, Di Bartolomeo M, Cabiddu M, Passalacqua R, de Braud F, Petrelli F. **Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.** *Cancers (Basel)*. 2019 Apr 5;11(4).
 74. Vernieri C, **Pusceddu S**, Fucà G, Indelicato P, Centonze G, Castagnoli L, Ferrari E, Ajazi A, Pupa S, Casola S, Foiani M, Mazzaferro V, Pruneri G, Milione M, de Braud F. **Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs).** *Int J Cancer*. 2019 Apr 1;144(7):1704-1712.
 75. **Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives.** Corti F, Nichetti F, Raimondi A, Niger M, Prinzi N, Torchio M, Tamborini E, Perrone F, Pruneri G, Di Bartolomeo M, de Braud F, **Pusceddu S**. *Cancer Treat Rev*. 2019 Jan;72:45-55.
 76. Co-autore del capitolo **Neuroendocrine tumors of the lung**. Autori: Marina Garassino, Giuseppe Lo Russo **Sara Pusceddu**, *Essentials for Clinicians ESMO 2019*.
 77. Milione M, Miceli R, Barretta F, Pellegrinelli A, Spaggiari P, Tagliabue G, Centonze G, Paolino C, Mangogna A, Kankava K, **Pusceddu S**, Giacomelli L, Corti A, Cotsoglou C, Mazzaferro V, Sozzi G, de Braud F, Pruneri G, Anichini A. **Microenvironment and Tumor Inflammatory Features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs).** *J Pathol Clin Res*. 2019 May 28.

78. Petrelli F, Ghidini A, Torchio M, Prinzi N, Trevisan F, Dallera P, De Stefani A, Russo A, Vitali E, Bruschi L, Costanzo A, Seghezzi S, Ghidini M, Varricchio A, Cabiddu M, Barni S, de Braud F, **Pusceddu S. Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis.** *Radiother Oncol.* 2019 May;134:211-219.
79. Cavalcoti F, **Pusceddu S**, Zilli A, Tamagno G, Femia D, Prinzi N, Travers J, Consonni D, Ciafardini C, Conte D, Massironi S. **Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm.** *Scand J Gastroenterol.* 2019 Aug 27:1-7.
80. Prinzi N, Raimondi A, Maccauro M, Milione M, Garanzini E, Torchio M, Corti F, Nichetti F, Lo Russo G, Giacomelli L, Mazzaferro V, Di Bartolomeo M, Seregini E, de Braud F, **Pusceddu S. Somatostatin analogs in association with peptide receptor radionuclide therapy in advanced well-differentiated NETs.** *Future Oncol.* 2019 Aug 19.
81. Milione M, Miceli R, Barretta F, Pellegrinelli A, Spaggiari P, Tagliabue G, Centonze G, Paolino C, Mangogna A, Kankava K, **Pusceddu S**, Giacomelli L, Corti A, Cotsoglou C, Mazzaferro V, Sozzi G, de Braud F, Pruner G, Anichini A. **Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.** *J Pathol Clin Res.* 2019 May 28.
82. **Pusceddu S**, Prinzi N, Raimondi A, Corti F, Buzzoni R, Di Bartolomeo M, Seregini E, Maccauro M, Coppa J, Milione M, Mazzaferro V, de Braud F. **Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.** *Tumori.* 2019 Apr;105(2):113-120.
83. Vernieri C, **Pusceddu S**, de Braud F. **Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors.** *Front Oncol.* 2019 Sep 20;9:902.
84. Panzuto F, **Pusceddu S**, Faggiano A, Rinzivillo M, Brighi N, Prinzi N, Riccardi F, Iannicelli E, Maggio I, Femia D, Tafuto S, Manuzzi L, Di Sarno A, Annibale B, de Braud F, Campana D; Itanet (Italian Association for Neuroendocrine Tumours). **Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations.** *Pancreatol.* 2019 Dec;19(8):1067-1073.
85. Busico A, Maisonneuve P, Prinzi N, **Pusceddu S**, Centonze G, Garzone G, Pellegrinelli A, Giacomelli L, Mangogna A, Paolino C, Belfiore A, Kankava K, Perrone F, Tamborini E, Pruner G, Fazio N, Milione M. **Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.** *Neuroendocrinology.* 2020;110(7-8):616-629.
86. Veltroni A, Cosaro E, Spada F, Fazio N, Faggiano A, Colao A, **Pusceddu S**, Zatelli MC, Campana D, Piovesan A, Pia A, Grossrubatscher EM, Filice A, Bianchi A, Razzore P, Toiari M, Cingolini S, Landoni L, Micciolo R, Davì MV. **Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study.** *Eur J Endocrinol.* 2020 Apr;182(4):439-446.
87. Lamberti G, Faggiano A, Brighi N, Tafuto S, Ibrahim T, Brizzi MP, **Pusceddu S**, Albertelli M, Massironi S, Panzuto F, Badalamenti G, Riccardi F, Butturini G, Gelsomino F, De Divitiis C, Modica R, Bongiovanni A, La Salvia A, Torchio M, Colao A, Ferone D, Campana D. **Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor.** *J Clin Endocrinol Metab.* 2020 Jan 1;105(1):dgz035.
88. Brighi N, Panzuto F, Modica R, Gelsomino F, Albertelli M, **Pusceddu S**, Massironi S, Lamberti G, Rinzivillo M, Faggiano A, Spallanzani A, Ferone D, Prinzi N, Rossi RE, Annibale B, Colao AM, Campana D. **Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study.** *Oncologist.* 2020 Mar;25(3):259-265.
89. **Pusceddu S**, Rossi RE, Torchio M, Prinzi N, Niger M, Coppa J, Giacomelli L, Sacco R, Facciorusso A, Corti F, Raimondi A, Prisciandaro M, Colombo E, Beninato T, Del Vecchio

M, Milione M, Di Bartolomeo M, de Braud F. **Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors.** J Clin Med. 2020 Aug 1;9(8):2468.

90. **One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches.** Niger M, Prisciandaro M, Antista M, Monica MAT, Cattaneo L, Prinzi N, Manglaviti S, Nichetti F, Brambilla M, Torchio M, Corti F, **Pusceddu S**, Coppa J, Mazzaferro V, de Braud F, Di Bartolomeo M. *World J Gastrointest Oncol.* 2020 Aug 15;12(8):833-849.
91. **Pusceddu S**, Vernieri C, Prinzi N, Torchio M, Coppa J, Antista M, Niger M, Milione M, Giacomelli L, Corti F, Prisciandaro M, Monteleone M, Colombo E, Di Bartolomeo M, de Braud F. **The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence.** *Therap Adv Gastroenterol.* 2020 Jul 31;13:1756284820927271.
92. Centonze G, Biganzoli D, Prinzi N, **Pusceddu S**, Mangogna A, Tamborini E, Perrone F, Busico A, Lagano V, Cattaneo L, Sozzi G, Roz L, Biganzoli E, Milione M. **Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups.** *Cancers (Basel).* 2020 Sep 24;12(10):2753.
93. **Pusceddu S**, Corti F, Milione M, Centonze G, Prinzi N, Torchio M, de Braud F. **Are Cyclin-Dependent Kinase 4/6 Inhibitors Without Future in Neuroendocrine Tumors?** *Oncologist.* 2020 Aug;25(8):e1257-e1258.
94. Facciorusso A, Abd El Aziz MA, Singh S, **Pusceddu S**, Milione M, Giacomelli L, Sacco R. **Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis.** *Cancers (Basel).* 2020 Apr 3;12(4):874.
95. Lamberti G, Brizzi MP, **Pusceddu S**, Gelsomino F, Di Meglio G, Massari F, Badalamenti G, Riccardi F, Ibrahim T, Ciccarese C, Buti S, Carnaghi C, Prinzi N, Panzuto F, Campana D. **Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis.** *J Clin Med.* 2020 May 5;9(5):1351.
96. Bharmal M, Nolte S, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, **Pusceddu S**, Hanna GJ, Hassel JC, Kiecker F, Ellers-Lenz B, Bajars M, Güzel G, Nghiem P, Hunger M, Schlichting M, Henry-Szatkowski M, D'Angelo SP. **Health-related quality of life trajectory of treatment-naïve patients with Merkel cell carcinoma receiving avelumab.** *Future Oncol.* 2020 Sep;16(27):2089-2099.
97. Brighi N, La Rosa S, Rossi G, Grillo F, **Pusceddu S**, Rinzivillo M, Spada F, Tafuto S, Massironi S, Faggiano A, Antonuzzo L, Santini D, Sessa F, Maragliano R, Gelsomino F, Albertelli M, Vernieri C, Panzuto F, Fazio N, De Divitiis C, Lamberti G, Colao A, Fave GD, Campana D. **Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study.** *Ann Surg.* 2020 Mar;271(3):527-533.
98. Panzuto F, Maccauro M, Campana D, Faggiano A, Massironi S, **Pusceddu S**, Spada F, Ferone D, Modica R, Grana CM, Ferolla P, Rinzivillo M, Badalamenti G, Zatelli MC, Gelsomino F, De Carlo E, Bartolomei M, Brizzi MP, Cingarlini S, Versari A, Fanciulli G, Arvat E, Merola E, Cives M, Tafuto S, Baldari S, Falconi M. **Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet).** *J Endocrinol Invest.* 2020 Aug 16:1-6.
99. Pietrantonio F, Morano F, Niger M, Corallo S, Antista M, Raimondi A, Prisciandaro M, Pagani F, Prinzi N, Nichetti F, Randon G, Torchio M, Corti F, Ambrosini M, Palermo F, Palazzo M, Biamonte L, Platania M, Sposito C, Cosimelli M, Mazzaferro V, **Pusceddu S**, Cremolini C, de Braud F, Di Bartolomeo M. **Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan.** *Clin Colorectal Cancer.* 2020 Sep;19(3):156-164.

100. Milione M, Maisonneuve P, Grillo F, Mangogna A, Centonze G, Prinzi N, **Pusceddu S**, Garzone G, Cattaneo L, Busico A, Bossi P, Spaggiari P, Pellegrinelli A, Del Gobbo A, Ferrero S, Kankava K, Pruner G, Rolli L, Roca E, Bercich L, Tironi A, Benvenuti MR, Gallazzi MS, Romano R, Berruti A, Pastorino U, Capella C. **Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis.** *Neuroendocrinology*. 2020 May 4.
101. **Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.** Bongiovanni A, Liverani C, **Pusceddu S**, Leo S, Di Meglio G, Tamberi S, Santini D, Gelsomino F, Pucci F, Berardi R, Lolli I, Bergamo F, Ricci S, Foca F, Severi S, Ibrahim T; SENECA Study Team Investigators. *BMJ Open*. 2020 Jul 19;10(7):e034393.
102. Facciorusso A, Abd El Aziz MA, Tartaglia N, Ramai D, Mohan BP, Cotsoglou C, **Pusceddu S**, Giacomelli L, Ambrosi A, Sacco R. **Microwave Ablation Versus Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials.** *Cancers (Basel)*. 2020 Dec 16;12(12):3796.
103. Yao JC, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruzsniowski P, Halperin DM, Li D, Tafuto S, Raj N, Campana D, Hijioka S, Raderer M, Guimbaud R, Gajate P, **Pusceddu S**, Reising A, Degtyarev E, Shilkrot M, Eddy S, Singh S. **Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms.** *Endocr Relat Cancer*. 2021 Jan 1:ERC-20-0382.R1.
104. Prinzi N, Rossi RE, Proto C, Leuzzi G, Raimondi A, Torchio M, Milione M, Corti F, Colombo E, Prisciandaro M, Cascella T, Spreafico C, Beninato T, Coppa J, Lo Russo G, Di Bartolomeo M, de Braud F, **Pusceddu S.** **Recent Advances in the Management of Typical and Atypical Lung Carcinoids.** *Clin Lung Cancer*. 2021 May;22(3):161-169.
105. **Pusceddu S**, Facciorusso A, Giacomelli L, Prinzi N, Corti F, Niger M, Milione M, Coppa J, Cascella T, Pulice I, Biamonte L, Papa S, Di Bartolomeo M, Shah A, Sacco R, de Braud F. **Target therapies plus somatostatin analogs in NETs: a network meta-analysis.** *Endocr Relat Cancer*. 2021 Jun 17;28(7):467-479.
106. Massironi S, Campana D, **Pusceddu S**, Albertelli M, Faggiano A, Panzuto F, Smirolto V, Andreasi V, Rossi RE, Maggio I, Torchio M, Dotto A, Modica R, Rinzivillo M, Carnaghi C, Partelli S, Fanetti I, Lamberti G, Corti F, Ferone D, Colao A, Annibale B, Invernizzi P, Falconi M; ItaNet (Italian Association for Neuroendocrine Tumours) Study Group. **Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study.** *Dig Liver Dis*. 2021 Mar;53(3):367-374.
107. Kankava K, Maisonneuve P, Mangogna A, Centonze G, Cattaneo L, Prinzi N, **Pusceddu S**, Fazio N, Pisa E, Di Domenico S, Bertani E, Mazzaferro V, Albertelli M, Grillo F, Milione M. **Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties.** *J Neuroendocrinol*. 2021 Aug;33(8):e13000.
108. Centonze G, Lagano V, Sabella G, Mangogna A, Garzone G, Filugelli M, Belmonte B, Cattaneo L, Crisafulli V, Pellegrinelli A, Simbolo M, Scarpa A, Spaggiari P, Brambilla T, **Pusceddu S**, Prinzi N, Anichini A, Tripodo C, Milione M. **Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms.** *J Clin Med*. 2021 Apr 17;10(8):1741.
109. Torchio M, Cattaneo L, Milione M, Prinzi N, Corti F, Ungari M, Anichini A, Mortarini R, Occhini A, Bertino G, Maurichi A, Coppa J, Di Bartolomeo M, de Braud FG, **Pusceddu S.** **Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma.** *Front Oncol*. 2021 Jun 17;11:628324.

110. **Pusceddu S.** Autore del capitolo **"NETs of the lung"** nel Manuale: **"Neuroendocrine Neoplasia Management: New Approaches for Diagnosis and Treatment"**. Edit Springer Nature 2021
111. **Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT.** Scalorbi F, Argiroffi G, Baccini M, Gherardini L, Fuoco V, Prinzi N, **Pusceddu S**, Garanzini EM, Centonze G, Kirienko M, Seregini E, Milione M, Maccauro M.Sci Rep. 2021 Sep 30;11(1):19490. doi: 10.1038/s41598-021-99048-8.
112. **Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study.** **Pusceddu S**, Vernieri C, Di Maio M, Prinzi N, Torchio M, Corti F, Coppa J, Buzzoni R, Di Bartolomeo M, Milione M, Regnault B, Truong Thanh XM, Mazzaferro V, de Braud F.Cancers (Basel). 2021 Dec 23;14(1):69. doi: 10.3390/cancers14010069.
113. **Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms.** Centonze G, Lagano V, Sabella G, Mangogna A, Garzone G, Filugelli M, Belmonte B, Cattaneo L, Crisafulli V, Pellegrinelli A, Simbolo M, Scarpa A, Spaggiari P, Brambilla T, **Pusceddu S**, Prinzi N, Anichini A, Tripodo C, Milione M.J Clin Med. 2021 Apr 17;10(8):1741. doi: 10.3390/jcm10081741.
114. **Metastatic pheochromocytomas and paragangliomas: where are we?** Prinzi N, Corti F, Torchio M, Niger M, Antista M, Pagani F, Beninato T, Pulice I, Rossi RE, Coppa J, Cascella T, Giacomelli L, Di Bartolomeo M, Milione M, de Braud F, **Pusceddu S**.Tumori. 2022 Dec;108(6):526-540. doi: 10.1177/03008916221078621. Epub 2022 May 20.
115. **Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective.** Prisciandaro M, Antista M, Raimondi A, Corti F, Morano F, Centonze G, Sabella G, Mangogna A, Randon G, Pagani F, Prinzi N, Niger M, Corallo S, Castiglioni di Caronno E, Massafra M, Bartolomeo MD, de Braud F, Milione M, **Pusceddu S**.Front Oncol. 2022 Feb 4;12:780716. doi: 10.3389/fonc.2022.780716. eCollection 2022.
116. **Lung carcinoid tumours: histology and Ki-67, the eternal rivalry.** Centonze G, Maisonneuve P, Simbolo M, Lagano V, Grillo F, Fabbri A, Prinzi N, Garzone G, Filugelli M, Pardo C, Mietta A, **Pusceddu S**, Sabella G, Bercich L, Mangogna A, Rolli L, Grisanti S, Benvenuti MR, Pastorino U, Roz L, Scarpa A, Berruti A, Capella C, Milione M.Histopathology. 2023 Jan;82(2):324-339. doi: 10.1111/his.14819. Epub 2022 Oct 26.
117. **Prognostic Factors Across Poorly Differentiated Neuroendocrine Neoplasms: a Pooled Analysis.** Centonze G, Maisonneuve P, Prinzi N, **Pusceddu S**, Albarello L, Pisa E, Barberis M, Vanoli A, Spaggiari P, Bossi P, Cattaneo L, Sabella G, Solcia E, La Rosa S, Grillo F, Tagliabue G, Scarpa A, Papotti M, Volante M, Mangogna A, Del Gobbo A, Ferrero S, Rolli L, Roca E, Bercich L, Benvenuti M, Messerini L, Inzani F, Pruneri G, Busico A, Perrone F, Tamborini E, Pellegrinelli A, Kankava K, Berruti A, Pastorino U, Fazio N, Sessa F, Capella C, Rindi G, Milione M.Neuroendocrinology. 2022 Nov 23. doi: 10.1159/000528186.
118. **Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications.** Simbolo M, Centonze G, Giudice L, Grillo F, Maisonneuve P, Gkountakos A, Ciaparrone C, Cattaneo L, Sabella G, Giugno R, Bossi P, Spaggiari P, Del Gobbo A, Ferrero S, Mastracci L, Fabbri A, Filugelli M, Garzone G, Prinzi N, **Pusceddu S**, Testi A, Monti V, Rolli L, Mangogna A, Bercich L, Benvenuti MR, Bria E, Pilotto S, Berruti A, Pastorino U, Capella C, Infante M, Milella M, Scarpa A, Milione M.Cancers (Basel). 2022 Sep 24;14(19):4653. doi: 10.3390/cancers14194653.
119. **Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study.** Ricci AD, **Pusceddu S**, Panzuto F, Gelsomino F, Massironi S, De Angelis CG, Modica R, Ricco G, Torchio M, Rinzivillo M, Prinzi N, Rizzi F, Lamberti G, Campana D.J Clin Med. 2022 Jan 28;11(3):713. doi: 10.3390/jcm11030713

120. **Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.** Pusceddu S, Prinzi N, Tafuto S, Ibrahim T, Filice A, Brizzi MP, Panzuto F, Baldari S, Grana CM, Campana D, Davì MV, Giuffrida D, Zatelli MC, Partelli S, Razzore P, Marconcini R, Massironi S, Gelsomino F, Faggiano A, Giannetta E, Bajetta E, Grimaldi F, Cives M, Cirillo F, Perfetti V, Corti F, Ricci C, Giacomelli L, Porcu L, Di Maio M, Seregini E, Maccauro M, Lastoria S, Bongiovanni A, Versari A, Persano I, Rinzivillo M, Pignata SA, Rocca PA, Lamberti G, Cingarlini S, Puliafito I, Ambrosio MR, Zanata I, Bracigliano A, Severi S, Spada F, Andreasi V, Modica R, Scalorbi F, Milione M, Sabella G, Coppa J, Casadei R, Di Bartolomeo M, Falconi M, de Braud F. JAMA Netw Open. 2022 Feb 1;5(2):e220290. doi: 10.1001/jamanetworkopen.2022.0290.
121. **MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers.** Niger M, Nichetti F, Casadei-Gardini A, Morano F, Pircher C, Tamborini E, Perrone F, Canale M, Lipka DB, Vingiani A, Agnelli L, Dobberkau A, Hülle J, Korell F, Heilig CE, Pusceddu S, Corti F, Droz M, Ulivi P, Prisciandaro M, Antista M, Bini M, Cattaneo L, Milione M, Glimm H, Köhler BC, Pruner G, Hübschmann D, Fröhling S, Mazzaferro V, Pietrantonio F, Di Bartolomeo M, de Braud F. Mol Oncol. 2022 Jul;16(14):2733-2746.
122. **Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastrointestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2.** Pusceddu S, Corti F, Prinzi N, Nichetti F, Ljevar S, Busico A, Cascella T, Leporati R, Oldani S, Pircher CC, Coppa J, Resi V, Milione M, Maccauro M, Miceli R, Tamborini E, Perrone F, Spreafico C, Niger M, Morano F, Pietrantonio F, Seregini E, Mariani L, Mazzaferro V, Di Liberti G, Fucà G, de Braud F, Vernieri C. J Hematol Oncol. 2023 Dec 14;16(1):119. Clinical Trial.
123. **Multidisciplinary Approach to the Diagnosis of Occult Primary Neuroendocrine Neoplasm: A Clinical Challenge.** Rossi RE, Corti F, Pusceddu S, Milione M, Coppa J, Masoni B, Oldani S, Sabella G, Cafaro P, Repici A. J Clin Med. 2023 Aug 25;12(17):5537.
124. **Lung carcinoid tumours: histology and Ki-67, the eternal rivalry.** Centonze G, Maisonneuve P, Simbolo M, Lagano V, Grillo F, Fabbri A, Prinzi N, Garzone G, Filugelli M, Pardo C, Mietta A, Pusceddu S, Sabella G, Bercich L, Mangogna A, Rolli L, Grisanti S, Benvenuti MR, Pastorino U, Roz L, Scarpa A, Berruti A, Capella C, Milione M. Histopathology. 2023 Jan;82(2):324-339.
125. **Digestive MiNENs: Could histological classification and molecular characterization drive clinical outcome and therapeutic approach?** Cattaneo L, Centonze G, Sabella G, Lagano V, Angerilli V, Pardo C, Bertani E, Spada F, Prinzi N, Pusceddu S, Fassan M, Fazio N, Milione M. Crit Rev Oncol Hematol. 2023 Aug;188:104044.
126. **Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled Analysis.** Centonze G, Maisonneuve P, Prinzi N, Pusceddu S, Albarello L, Pisa E, Barberis M, Vanoli A, Spaggiari P, Bossi P, Cattaneo L, Sabella G, Solcia E, La Rosa S, Grillo F, Tagliabue G, Scarpa A, Papotti M, Volante M, Mangogna A, Del Gobbo A, Ferrero S, Rolli L, Roca E, Bercich L, Benvenuti M, Messerini L, Inzani F, Pruner G, Busico A, Perrone F, Tamborini E, Pellegrinelli A, Kankava K, Berruti A, Pastorino U, Fazio N, Sessa F, Capella C, Rindi G, Milione M. Neuroendocrinology. 2023;113(4):457-469.
127. **Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.** Corti F, Brizzi MP, Amoroso V, Giuffrida D, Panzuto F, Campana D, Prinzi N, Milione M, Cascella T, Spreafico C, Randon G, Oldani S, Leporati R, Scotto G, Pulice I, Stocchetti BL, Porcu L, Coppa J, Di Bartolomeo M, de Braud F, Pusceddu S. BMC Cancer. 2023 Sep 26;23(1):908.
128. **Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study.** Ruggeri RM, Altieri B, Razzore P, Retta F, Sperti E, Scotto G, Brizzi MP, Zumstein L, Pia A, Lania A, Lavezzi E, Nappo G, Laffi A, Albertelli M, Boschetti M, Hasballa I, Veresani A, Prinzi N, Pusceddu S, Oldani S, Nichetti F, Modica R, Minotta R, Liccardi A, Cannavale G, Grossrubatscher EM, Tarsitano MG, Zamponi V, Zatelli MC, Zanata I, Mazzilli R,

- Appetecchia M, Davì MV, Guarnotta V, Giannetta E, La Salvia A, Fanciulli G, Malandrino P, Isidori AM, Colao A, Faggiano A; NIKE Group. *J Endocrinol Invest*. 2024 Apr;47(4):959-971.
129. **COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study.** Fazio N, Gervaso L, Halfdanarson TR, Sonbol M, Eiring RA, **Pusceddu S**, Prinzi N, Lombardi Stocchetti B, Grozinsky-Glasberg S, Gross DJ, Walter T, Robelin P, Lombard-Bohas C, Frassoni S, Bagnardi V, Antonuzzo L, Sparano C, Massironi S, Gelsomino F, Bongiovanni A, Ranallo N, Tafuto S, Rossi M, Cives M, Rasul Kakil I, Hamid H, Chirco A, Squadroni M, La Salvia A, Hernando J, Hofland J, Koumariou A, Boselli S, Tamayo D, Mazzon C, Rubino M, Spada F. *Endocr Relat Cancer*. 2023 Apr 26;30(6):e220395. doi: 10.1530/ERC-22-0395. Print 2023 Jun 1.
 130. **Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Enteropancreatic Neuroendocrine Tumors (G3 GEP-NET).** Lamberti G, Prinzi N, Bongiovanni A, Torniai M, Andriani E, Biase D, Malvi D, Mosca M, Berardi R, Ibrahim T, **Pusceddu S**, Campana D. *Diagnostics (Basel)*. 2023 Apr 29;13(9):1595. doi: 10.3390/diagnostics13091595.
 131. **Ascl1 and OTP tumour expressions are associated with disease-free survival in lung atypical carcinoids.** Centonze G, Maisonneuve P, Simbolo M, Lagano V, Grillo F, Prinzi N, **Pusceddu S**, Missiato L, Colantuono M, Sabella G, Bercich L, Mangogna A, Rolli L, Grisanti S, Benvenuti MR, Pastorino U, Roz L, Scarpa A, Berruti A, Capella C, Milione M. *Histopathology*. 2023 May;82(6):870-884.
 132. **Author Correction: Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT.** Scalorbi F, Argiroffi G, Baccini M, Gherardini L, Fuoco V, Prinzi N, **Pusceddu S**, Garanzini EM, Centonze G, Kirienko M, Seregini E, Milione M, Maccauro M. *Sci Rep*. 2023 Jan 31;13(1):1759. doi: 10.1038/s41598-023-28977-3.
 133. **Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST.** de Mestier L, Resche-Rigon M, Dromain C, Lamarca A, La Salvia A, de Baker L, Fehrenbach U, **Pusceddu S**, Colao A, Borbath I, de Haas R, Rinzivillo M, Zerbi A, Funicelli L, de Herder WW, Selberherr A, Wagner AD, Manoharan P, De Cima A, Lybaert W, Jann H, Prinzi N, Faggiano A, Annet L, Walenkamp A, Panzuto F, Pedicini V, Pitoni MG, Siebenhuener A, Mayerhoefer ME, Ruzniewski P, Vullierme MP. *J Neuroendocrinol*. 2023 Jun;35(6):e13311.
 134. **NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.** Nichetti F, Rota S, Ambrosini P, Pircher C, Gusmaroli E, Droz Dit Busset M, **Pusceddu S**, Sposito C, Coppa J, Morano F, Pietrantonio F, Di Bartolomeo M, Mariani L, Mazzaferro V, de Braud F, Nigam M. *JAMA Netw Open*. 2024 Jan 2;7(1):e2350756.
 135. **Comprehensive genomic and transcriptomic characterization of high-grade gastro-enteropancreatic neoplasms.** Angerilli V, Sabella G, Simbolo M, Lagano V, Centonze G, Gentili M, Mangogna A, Coppa J, Munari G, Businello G, Borga C, Schiavi F, **Pusceddu S**, Leporati R, Oldani S, Fassan M, Milione M. *Br J Cancer*. 2024 Jul;131(1):159-170. doi: 10.1038/s41416-024-02705-8. Epub 2024 May 10. PMID: 38729995 **Free PMC article**.
 136. **Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma.**
 137. Laganà M, Habra MA, Remde H, Almeida MQ, Cosentini D, **Pusceddu S**, Grana CM, Corssmit EPM, Bongiovanni A, De Filipo G, Lim ES, Zamparini M, Grisanti S, Deutschbein T, Fassnacht M, Fagundes GFC, Pereira MAA, Oldani S, Rota S, Prinzi N, Jimenez C, Berruti A. *Eur J Cancer*. 2024 Sep;208:114122.
 138. **A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas.** Bongiovanni A, Liverani C, Foca F, Bergamo F, Leo S, **Pusceddu S**, Gelsomino F, Brizzi MP, Di Meglio G, Spada F, Tamberi S, Lolli I, Cives M, Marconcini R, Pucci F, Berardi R, Antonuzzo L, Badalamenti G, Santini D, Recine F, Vanni S, Tebaldi M, Severi S, Rudnas B, Nanni O, Ranallo N, Crudi L, Calabrò L, Ibrahim T. *Eur J Cancer*. 2024 Sep;208:114129. doi: 10.1016/j.ejca.2024.114129.
 139. **Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial.** Nasca V, Prinzi N, Coppa J, Prisciandaro M,

- Oldani S, Ghelardi F, Conca E, Capone I, Busico A, Perrone F, Tamborini E, Sabella G, Greco G, Greco FG, Tafuto S, Procopio G, Morano F, Niger M, Maccauro M, Milione M, de Braud F, Pietrantonio F, **Pusceddu S**. *Eur J Cancer*. 2024 Sep;209:114276.
140. **Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database.** Panzuto F, Partelli S, Campana D, de Braud F, Spada F, Cives M, Tafuto S, Bertuzzi A, Gelsomino F, Bergamo F, Marcucci S, Mastrangelo L, Massironi S, Appetecchia M, Filice A, Badalamenti G, Bartolomei M, Amoroso V, Landoni L, Rodriquez MG, Valente M, Colao A, Isidori A, Fanciulli G, Bollina R, Ciola M, Butturini G, Marconcini R, Arvat E, Cinieri S, Berardi R, Baldari S, Riccardi F, Spoto C, Giuffrida D, Gattuso D, Ferone D, Rinzivillo M, Bertani E, Versari A, Zerbi A, Lamberti G, Lauricella E, **Pusceddu S**, Fazio N, Dell'Unto E, Marini M, Falconi M. *Endocrine*. 2024 Apr;84(1):42-47.
 141. **Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort.** Panzuto F, Andrini E, Lamberti G, **Pusceddu S**, Rinzivillo M, Gelsomino F, Raimondi A, Bongiovanni A, Davi MV, Cives M, Brizzi MP, Persano I, Zatelli MC, Puliafito I, Tafuto S, Campana D. *J Clin Med*. 2024 Apr 3;13(7):2074.
 142. **Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives.** Corti F, Rossi RE, Cafaro P, Passarella G, Turla A, **Pusceddu S**, Coppa J, Oldani S, Guidi A, Longarini R, Cortinovis DL. *Cancers (Basel)*. 2024 May 27;16(11):2025.
 143. **Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer.** Nichetti F, Silvestri M, Agnelli L, Franza A, Pircher C, Rota S, Ambrosini P, Fotia G, Hülle J, Randon G, Lajer P, Perrone F, Tamborini E, Leoncini G, Coppa J, Busset MDD, **Pusceddu S**, Milione M, Morano F, Pietrantonio F, Pruner G, Mazzaferro V, Lipka DB, Köhler BC, Hübschmann D, Fröhling S, de Braud F, Niger M. *Cancer Med*. 2024 Dec;13(23):e70393.
 144. **Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study.** Ruggeri RM, Altieri B, Razzore P, Retta F, Sperti E, Scotto G, Brizzi MP, Zumstein L, Pia A, Lania A, Lavezzi E, Nappo G, Laffi A, Albertelli M, Boschetti M, Hasballa I, Veresani A, Prinzi N, **Pusceddu S**, Oldani S, Nichetti F, Modica R, Minotta R, Liccardi A, Cannavale G, Grossrubatscher EM, Tarsitano MG, Zamponi V, Zatelli MC, Zanata I, Mazzilli R, Appetecchia M, Davi MV, Guarnotta V, Giannetta E, La Salvia A, Fanciulli G, Malandrino P, Isidori AM, Colao A, Faggiano A; NIKE Group. *J Endocrinol Invest*. 2024 Apr;47(4):959-971.
 145. **Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectives.** Simbolo M, Centonze G, Gkoutakos A, Monti V, Maisonneuve P, Golovco S, Sabella G, Del Gobbo A, Gobbo S, Ferrero S, Fabbri A, Pardo C, Garzone G, Prinzi N, **Pusceddu S**, Testi A, Rolli L, Mangogna A, Bercich L, Benvenuti MR, Bria E, Pilotto S, Berruti A, Pastorino U, Capella C, Infante M, Milella M, Scarpa A, Milione M. *Virchows Arch*. 2024 May;484(5):777-788.
 146. **An Italian real-world multicenter study of patients with advanced mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) of the gastro-entero-pancreatic system treated with chemotherapy.** Spada F, Milione M, Maisonneuve P, Prinzi N, Smiroldo V, Bolzacchini E, **Pusceddu S**, Carnaghi C, Sessa F, La Rosa S, Uccella S, Fazio N. *J Endocrinol Invest*. 2024 Sep;47(9):2279-2294.
 147. **The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [¹⁷⁷Lu]Lu-DOTATATE.**
 148. **Maccauro M, Cuomo M, Bauckneht M, Bagnalasta M, Mazzaglia S, Scalorbi F, Argiroffi G, Kirienko M, Lorenzoni A, Aliberti G, **Pusceddu S**, Giuseppina C, Matteo GE, Seregni E, Chiesa C.** *Eur J Nucl Med Mol Imaging*. 2024 Dec;52(1):291-304.
 149. **Cylindrical TGR as early radiological predictor of RLT progression in GEPNETs: a proof of concept.** Scalorbi F, Garanzini EM, Calareso G, Marzi C, Di Rocco G, Argiroffi G, Baccini M, **Pusceddu S**, Marchianò A, Maccauro M. *Sci Rep*. 2024 Jul 9;14(1):15782.
 150. **Pathological Characteristics, Management, and Prognosis of Rectal Neuroendocrine Tumors: A Retrospective Study from a Tertiary Hospital.** Cavalcoli F, Rausa E, Ferrari D, Rosa R, Maccauro M, **Pusceddu S**, Sabella G, Cantù P, Vitellaro M, Coppa J, Mazzaferro V. *Diagnostics (Basel)*. 2024 Aug 28;14(17):1881.

151. Capecitabine and temozolomide or temozolomide alone in patients with atypical carcinoids. Galvani L, Zappi A, **Pusceddu S**, Gelsomino F, La Salvia A, Oldani S, Panzuto F, Andrini E, Lamberti G, Campana D. *Endocrine*. 2025 Jan 24.
152. **Oncocytic and spindle cell typical carcinoids of lung: different immunophenotype and biological behavior.** Sabella G, Centonze G, Maisonneuve P, Grillo F, Lagano V, Garzone G, Pardo C, Filugelli M, Mietta A, Simbolo M, Fabbri A, Mangogna A, Prinzi N, **Pusceddu S**, Rolli L, Bercich L, Grisanti S, Benvenuti MR, Pastorino U, Roz L, Scarpa A, Berruti A, Capella C, Milione M. *J Pathol Clin Res*. 2025 Mar;11(2):e70020.

La sottoscritta è a conoscenza che, ai sensi dell'art.76 DPR 28/12/2000 n.445, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, la sottoscritta autorizza al trattamento dei dati personali, secondo quanto previsto dal D. lgs. 196/03.

Milano, 15/04/2025

NOME E COGNOME (FIRMA)

A handwritten signature in black ink, appearing to read "Sara Pardo", followed by a long horizontal line extending to the right.